COVID-19 patients who are vaccinated -- and were hospitalized with reduced kidney function -- had better outcomes than unvaccinated patients, a new study finds.

Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

Recipients of the Pfizer mRNA vaccine experienced more all-cause deaths within the first 100 days post-vaccination than ...

Vaccinated patients hospitalized with COVID-19 who developed acute kidney injury had better outcomes than unvaccinated patients with the same condition, new research suggests. The study found ...

Imagine a world without COVID-19 vaccines: a terrifying reality of endless variants, overwhelmed hospitals, and economies in ...

The American College of Obstetricians and Gynecologists is urging insurers to continue covering vaccinations during pregnancy in an open letter signed by 30 prominent professional health organizations ...

Some appointees hold some of Kennedy’s more critical views on vaccines, while other picks appear to be olive branches to ...

Now that Covid vaccines are no longer recommended for healthy children and pregnant people, boosters could be a lot more ...

BioNTech said Thursday it would buy CureVac, its onetime competitor in the Covid-19 vaccine race, for about $1.25 billion in ...

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two ...

Its dividend: The stock recently yielded a whopping 7.3%. That's hard to beat and will generate around $730 for every $10,000 ...